EGFR and non-small cell lung carcinoma: This retrospective study showed a 74.5% ORR, 97.9% DCR, a median PFS of 11 months and a median OS of 31 months in stage IV EGFR mutation-positive NSCLC patients treated of first- or higher-line EGFR-TKIs, which was similar to previous reports [15, 12–14].